Electra Therapeutics files Form 3 detailing Westlake BioPartners ownership

Electra Therapeutics Form 3 filed Sept. 21, 2026, showing Westlake BioPartners entities reporting 10% beneficial ownership. Westlake BioPartners Fund I reported indirect ownership of 3,527,136 common shares, and Westlake BioPartners Fund II reported indirect ownership of 2,820,403 common shares. Shares were received via automatic 1:1 conversion of redeemable preferred stock at the IPO closing, with no additional consideration.